Roche to invest $50 billion in the U.S. as tariff threat lingers
Swiss pharmaceutical giant Roche on Tuesday said that it would invest $50 billion in the United States.
Roche to Invest $50 Billion in U.S. Manufacturing, R&D Amid Tariff Threats
The pharma giant said the investment would create more than 12,000 new jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump's tariff threats.
Roche to invest $50 billion in United States over next five years
Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward investment moves by companies dealing with President Donald Trump's tariffs policy.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
Roche: Forget Tariffs And Focus On The Positives -- There Are Many
The Trump administration's proposed tariffs on pharmaceuticals have caused significant stock declines, but their implementation remains uncertain and may be aimed at achieving specific goals. Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a resilient investment. Roche's promising pipeline, particularly in obesity drugs, and its solid financial performance suggest long-term growth potential despite recent stock volatility.
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche Holdings AG RHHBY on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases.
South Korea needs political reform to attract investor interest: David Roche
David Roche, strategist at Quantum Strategy, and Victor Cha, president of the CSIS geopolitics and foreign policy department, discuss the possibility of constitutional reform in South Korea.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RMS) compared with the currently approved Ocrevus IV 600 mg dose.
Roche fails in bid to increase dose of MS drug Ocrevus
Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the standard dose, a setback in a bid to further boost usage of the best-selling therapy.
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
Roche Holding, Comcast, Eaton Corp and National Presto Industries are included in this Analyst Blog.
